1. Generics Bulletin
  2. >>Products

Alvotech Differentiation Plans Include Interchangeable Golimumab

Icelandic Company Details Strategy Amid Proposed SPAC Merger

 
• By Dean Rudge

A proposal to merge with a special purpose acquisition company, in a move that will deliver longstanding plans for a public listing, has led biosimilars specialist Alvotech to discuss its ambitions and goals for its pipeline of seven biosimilar candidates.

US dollars on yellow background
Alvotech anticipates more than $400m of fresh capital under the merger • Source: Alamy

Amid its proposed merger with a blank check company that would enable it to trade its shares publicly on one of the US’s largest stock exchanges, Alvotech has disclosed previously safeguarded strategic and financial goals, underpinned by the firm’s desire to differentiate from its competitors in order to be “the world’s leading biosimilars company.”

Alongside targeting potential in-licensing opportunities – after Alvogen’s biosimilars sister company struck historically a multitude of commercialization deals across the globe for its projects – the Iceland-based firm believes its R&D

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

 
• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

More from Products